BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260512
DTEND;VALUE=DATE:20260515
DTSTAMP:20260514T215123
CREATED:20260217T122509Z
LAST-MODIFIED:20260217T122509Z
UID:42924-1778544000-1778803199@www.pharmajournalist.com
SUMMARY:Investigative & Preclinical Toxicology Summit 2026
DESCRIPTION:Optimize Model Selection\, Accelerate Timelines\, Improve Predictivity of Toxicity \nDates: May 12-14 | Location: Boston\, MA \nWhy Attend \nWith nearly 90% of drug candidates failing in the clinic and one-third of those failures driven by safety preclinical toxicology has reached a critical inflection point. Traditional models are no longer sufficient to predict human risk\, leading to costly late-stage attrition and stalled pipelines. \nThe 2026 summit marks a new era for toxicology. Following the FDA’s 2025 roadmap to reduce reliance on animal testing\, adoption of New Approach Methodologies (NAMs)\, including in vitro\, microphysiological\, and computational models\, is accelerating. CROs and technology developers are releasing innovative platforms\, but challenges remain around predictivity\, validation standards\, and regulatory alignment. \nWhat You’ll Learn \nThis industry-led forum is the only meeting dedicated to benchmarking what truly works in predictive toxicology. Key focus areas include: \n\nEvaluating in vivo\, in vitro\, and in silico strategies\nSharing real IND case studies\nDefining fit-for-purpose model selection across modalities\nAdvancing NAM adoption while ensuring regulatory compliance\n\nWho Should Attend \nIf you are responsible for: \n\nDe-risking first-in-human decisions\nImplementing innovative toxicology strategies\nImproving safety translation from preclinical to clinic\n\n…this summit is your essential forum to separate innovation from hype and build strategies that stand up both clinically and regulatorily. \n📥 Download the Event Guide to explore the full agenda\, speakers\, and registration details: \nOrganiser Name: Hanson Wade\nContact: Nisha Poyser-Reid\ninfo@hansonwade.com\n(+1) 617 455 4188
URL:http://www.pharmajournalist.com/event/investigative-preclinical-toxicology-summit-2026/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson  Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260518
DTEND;VALUE=DATE:20260521
DTSTAMP:20260514T215123
CREATED:20260128T093131Z
LAST-MODIFIED:20260128T093339Z
UID:42798-1779062400-1779321599@www.pharmajournalist.com
SUMMARY:7th TCR-Based Therapies Summit
DESCRIPTION:New assets have entered clinic\, whilst dozens more have been disclosed\, and recent investments such as\, T-Therapeutics’ $91M Series A extension to advance their bispecific towards the clinic and Anocca’s SEK 440M raise\, pinpoint how funding and portfolio decisions have the power to define the trajectory of the TCR field. \nIt is in this context that the 7th TCR-Based Therapies Summit returns to unite fellow biopharma experts in address shared challenges and to bridge the gap between promising clinical data and long-term\, commercially viable TCR-based approaches. \nAcross three focused days\, enter into open discussions\, benchmark with peers\, participate in practical problem-solving and hear new data in presentations led by Immunocore\, Enara Bio\, Regeneron\, Eureka Therapeutics\, T-Cypher Bio\, Zelluna Immunotherapy\, and Aethon Therapeutics. \nJoin us in empowering the community to shape a more durable\, scalable\, and commercially robust future for TCR-based therapies. \nTo know more visit: https://ter.li/uhpzx3
URL:http://www.pharmajournalist.com/event/7th-tcr-based-therapies-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260519
DTEND;VALUE=DATE:20260522
DTSTAMP:20260514T215123
CREATED:20260211T085701Z
LAST-MODIFIED:20260211T085701Z
UID:42865-1779148800-1779407999@www.pharmajournalist.com
SUMMARY:4th Nasal Formulation & Delivery Summit
DESCRIPTION:Biopharma investment into the formulation\, delivery\, and commercialization of intranasal therapies is at an all-time high\, and there has never been such an opportunistic time to pursue nasal delivery. Alongside the market projection for intranasal therapies being forecasted to reach $21.2 billion by 2032\, 2025 breakthroughs included Atzumi being approved for migraine treatment\, and Eli Lilly’s Baqsimi now being applied to severe Hypoglycemia. The clock is ticking for biopharma to master their formulations first time for systemic and CNS targeting\, streamline preclinical and clinical trial success\, and achieve regulatory approval to drive products to market. \nIn response to this recent momentum\, the 4th Nasal Formulation & Delivery Summit is uniting 70+ biopharma professionals across C-levels\, Formulation\, Intranasal\, and roduct Development to overcome drug and device combination challenges\, perfect preclinical translation\, and alter formulations\, to achieve commercial viability for intranasal products. This is the only forum specifically dedicated to industry-focused intranasal formulation\, targeting both systemic and CNS delivery. We will combine a hyper-relevant technical focus with a commercial angle to help see your products through concept to clinic. \nIn uniting large pharma\, expanding mid-sized biotech\, and startup innovators\, you will achieve technical excellence for your formulation and delivery that will future-proof commercialization\, and meet potential partners who will co-develop your intranasal therapies. Adopt groundbreaking insights on pre-clinical and clinical intranasal study data for different delivery methods to obtain practical takeaways that will transform the trajectory of your intranasal success. Join biopharma in igniting a new era of innovation where intranasal delivery holds the power to unparalleled medical benefits. \nTo know more visit: https://ter.li/eqlf0s
URL:http://www.pharmajournalist.com/event/4th-nasal-formulation-delivery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260519
DTEND;VALUE=DATE:20260522
DTSTAMP:20260514T215123
CREATED:20260217T121251Z
LAST-MODIFIED:20260217T124142Z
UID:42916-1779148800-1779407999@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences West
DESCRIPTION:Returning for its 8th year\, LEAP HR: Life Sciences West brings together 100+ senior HR leaders from scaling and stabilizing biotech organizations to navigate volatility and drive measurable business impact. \nAcross three days of high-impact sessions\, including case studies\, benchmarking\, roundtables\, and structured networking\, attendees will gain practical strategies to build lean HR functions\, retain top talent\, and respond to immigration shifts and political change. \nThis is the only forum dedicated to the unique people challenges facing West Coast life sciences organizations. Join us this May to connect\, benchmark\, and lead with confidence in a rapidly evolving market. \nTo know more visit: https://ter.li/caoti5
URL:http://www.pharmajournalist.com/event/leap-hr-life-sciences-west-2026/
LOCATION:Wyndham San Diego Bayside\, 1355 N Harbor Dr\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
END:VCALENDAR